Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer

Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer

To investigate the efficacy and safety of bicalutamide (Casodex) with its clinically recommended dose, the randomized early phase II study was performed in 124 patients with prostatic cancer (stage C, D). The patients were given 50, 80 or 100 mg of bicalutamide orally once a day in fixed doses for 1...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 42(1996), 2 vom: 23. Feb., Seite 157-68
1. Verfasser: Kotake, T (VerfasserIn)
Weitere Verfasser: Usami, M, Isaka, S, Shimazaki, J, Nakano, E, Okuyama, A, Okajima, E, Kanetake, H, Saitoh, Y, Kumamoto, Y, Orikasa, S, Sakata, Y, Hosaka, M, Akaza, H, Koiso, K, Honma, Y, Aso, Y, Oishi, K, Yoshida, O, Naitoh, S, Kumazawa, J, Koyanagi, T, Yachiku, S, Shiraiwa, Y, Tsukagoshi, S
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 1996
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Clinical Trial Clinical Trial, Phase II English Abstract Journal Article Multicenter Study Randomized Controlled Trial Androgen Antagonists Anilides Antineoplastic Agents Biomarkers, Tumor mehr... Nitriles Tosyl Compounds bicalutamide A0Z3NAU9DP